ClinicalTrials.gg
RecruitingNCT05332639Updated Jan 30, 2026

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

An interventional study of Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool and Standard Crohn's Disease Education in Inflammatory Bowel Diseases, Crohn Disease and Crohn Colitis, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Primary conditionCrohn DiseaseRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Crohn Disease
Why
  1. The study's listed conditions name Crohn Disease, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Crohn Disease by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Crohn Disease · Massachusetts General Hospital.

Started
2025
with 1 other
No phase
8 of 14
4 open now
Registered
9th of 14
by date

Among the 14 studies in Crohn Disease by Massachusetts General Hospital, this one is one of 2 that started in 2025, is one of 8 with no phase, and was the 9th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 14 studies in Crohn Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 14 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Crohn Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and biomarkers associated with risk for Crohn's disease in unaffected first-degree relatives of patients with inflammatory bowel disease. We hypothesize that personalized risk disclosure via the PRE-Crohn's educational tool is both feasible and successful in modifying behaviors associated with Crohn's disease risk and normalizing pre-clinical disease biomarkers when compared to standard Crohn's disease education. Broadly, completion of this project will also help elucidate the role of lifestyle and dietary factors in pre-clinical Crohn's disease development in high-risk individuals, and provide novel insight into potential strategies for disease prevention in this population.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Crohn Colitis
  • Crohn's Ileocolitis
  • Crohn's Gastritis
  • Crohn's Jejunitis
  • Crohn's Duodenitis
  • Crohn's Esophagitis

Browse trials for

Keywords

  • Crohn's disease
04

In context

Crohn Disease Reclassified

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

This study's planned enrollment of 80 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to give
  • Ability and willingness to comply with all patient visits and study-related procedures
  • Ability to understand and complete study questionnaires
  • Must have at least one first-degree relative with inflammatory bowel disease (Crohn's disease, ulcerative colitis, or indeterminate colitis/IBD unclassified)
  • Individuals greater than 14 years of age

Exclusion criteria

Exclusion Criteria:

  • Inability to provide
  • Inability to comply with all patient visits and study-related procedures
  • Inability to understand or complete study questionnaires
  • Patients with existing diagnoses of inflammatory bowel disease (ulcerative colitis, Crohn's disease, or indeterminate colitis/IBD unclassified)
  • Evidence of clinical signs or symptoms of inflammatory bowel disease, identified by a modified version of the Harvey-Bradshaw Index for CD activity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool

    Behavioral: Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool

  • Active comparator
    Comparator arm

    Standard Crohn's Disease Education

    Behavioral: Standard Crohn's Disease Education

Interventions

  • BehavioralPersonalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool

    We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.

    Also known as: Intervention Arm

  • BehavioralStandard Crohn's Disease Education

    The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.

    Also known as: Comparator Arm

07

What researchers measure

Primary outcomes

  1. Total enrollment (n) at 1.5 years and retention rate (%) at study conclusion

    The total enrollment at 1.5 years and the retention rate recorded at the conclusion of the study will be measured based on completion of the 6-month survey.

    Time frame: 1.5 years and time of study completion

Secondary outcomes

  1. Motivation to change smoking behavior

    We will measure change in contemplation ladder scores for motivation to change smoking behavior (yes/no for achieving a 1-point increase)

    Time frame: 8 weeks and 6 months

  2. Motivation to change diet

    We will measure change in contemplation ladder scores for motivation to change diet (yes/no for achieving a 1-point increase)

    Time frame: 8 weeks and 6 months

  3. Motivation to change physical activity

    We will measure change in contemplation ladder scores for motivation to change physical activity (yes/no for achieving a 1-point increase)

    Time frame: 8 weeks and 6 months

  4. Change in physical activity

    We will measure change in physical activity (MET-hours/week)

    Time frame: 8 weeks and 6 months

  5. Change in fruit intake

    We will measure change in fruit intake (servings/day)

    Time frame: 8 weeks and 6 months

  6. Change in vegetable intake

    We will measure change in vegetable intake (servings/day)

    Time frame: 8 weeks and 6 months

  7. Change in processed meat intake

    We will measure change in processed meat intake (servings/day)

    Time frame: 8 weeks and 6 months

  8. Change in fiber intake

    We will measure change in fiber intake (grams/day)

    Time frame: 8 weeks and 6 months

  9. Change in added sugar intake

    We will measure change in added sugar intake (grams/day)

    Time frame: 8 weeks and 6 months

  10. Change in smoking behaviors

    We will measure change in smoking behaviors including current smoking vs non-smoking and cigarettes/day

    Time frame: 8 weeks and 6 months

  11. Change in C-reactive protein (CRP; mg/L)

    We will measure change in CRP (mg/L)

    Time frame: 8 weeks and 6 months

  12. Change in fecal calprotectin (mcg/g)

    We will measure change in fecal calprotectin (mcg/g)

    Time frame: 8 weeks and 6 months

  13. Change in seropositivity for antimicrobial biomarkers

    We will measure several Crohn's disease associated antimicrobial biomarkers including ASCA IgA and IgG, anti-OmpC, anti-CBir1, anti-A4-Fla2 and anti-FlaX will be assayed using the PROMETHEUS® IBD sgi Diagnostic® panel. Positivity for each of these components are defined as follows: ASCA IgA \> 9.2 EU/mL; ASCA IgG \> 11.9 EU/mL; anti-OmpC \> 11.3 EU/mL; anti-CBir1 \> 35.4 EU/mL; anti-A4-Fla2 \> 32.4 EU/mL and anti-FlaX \> 36.0 EU/mL. Total biomarker positivity (secondary outcome) will be defined as the presence of 1 or more positive individual biomarkers above. We will then assess for change in total biomarker positivity at 8 weeks and 6 months compared to baseline.

    Time frame: 8 weeks and 6 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Colditz GA, Dart H. Commentary: 20 years online with "Your Disease Risk". Cancer Causes Control. 2021 Jan;32(1):5-11. doi: 10.1007/s10552-020-01356-3. Epub 2020 Oct 17. PubMed 33068181 ↗

Individual participant data

Plan to share: Yes — Aggregate-level results of from this study will be reported on clinicaltrials.gov. De-identified individual-level data will be uploaded to a separate controlled access repository and can be available upon reasonable request and per controlled access repository standard terms and procedures.

Time frame: All scientific data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the funding period.

Access criteria: A controlled repository will be used to store and protect individual patient data. To access data arising from this project, users must complete a data request form and Data Use Agreement (DUA), which limits subsequent use to the terms of the approved request and requires that users maintain data security, and refrain from any attempts to re-identify research participants or engage in any unauthorized uses of the data. To get access to the data, the user must submit a valid scientific question, include a statistical analysis plan.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2027, 25 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 25 months is below that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 18, 2022
StartActual
Oct 3, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05332639
Collaborators
American College of Gastroenterology, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Emily R. Lopes, MD, MPH (Principal Investigator, Instructor of Medicine, Harvard Medical School, Massachusetts General Hospital) — Principal investigator
First posted
Apr 18, 2022
Start date
Oct 3, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Emily W Lopes, MD
Contact
mghprecrohns@mgb.org
617-726-5560
Emily Lopes, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion